Human genome project has unraveled 24,000 human genes. Human genetic research for single-gene related disease has been redirected to diseases with more complex etiologies like insulin dependent diabetes mellitus, multiple sclerosis and psychiatric illnesses. Often being of multiple gene origin, these high incidence diseases cause mortality and morbidity in a wide population. The further step in research will be to study the functions of these genes and their proteins and also the interaction between genes and proteins in general. In order to reach the primary target, clinical applicable therapeutics, an extended technology platform is needed comprising at least: A high throughput genotyping facility; to determine the identity of genes involved, facilities, bio-informatics facilities to give access to DNA databanks, protein banks etc; well-equipped laboratories for molecular biology to identify genes and to set up tests for diagnosis; transgenic animal production sites to develop animal models; GMP production facilities to produce DNA-based therapeutics; development of high performance non-toxic pharmaceutical delivery systems for DNA-based therapy; facilities for preclinical tests; and a network of experienced clinical researchers for phase I-III clinical trials.

From the clinical / pharmaceutical perspective the development of DNA-mediated therapy based therapies has just begun. Although 20 years of research has been spent on gene therapy based on viral vector technology, these applications underwent a drawback by the death of first trial patients. A 100% synthetic delivery system is an urgent need for biochemists, cell biologists as well as molecular biologists all over the globe. These labeling devices such as ligands, peptides, antibodies, fluorescent dye, single well carbon nanotube and magnetic beads have to be bound to the delivery system, to be able to study cellular (transport) mechanisms. DNA immunization to discover novel therapeutic antibodies, in vitro and in vivo tansfection studies including pre clinical trials is hottest areas of research. It offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by the same standard technique that is readily amenable to automation. We assure our home made antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein. For years, our team has been well known for high-quality, fast turn-around plasmid DNA production services. These include production of individual constructs for researchers as well as large scale manufacturing for biotech suppliers and pharmaceutical companies with complete dedication to long term ultimate success. Our large scale plasmid manufacturing through magnetic beads technology is cost effective and efficient way to achieve the need of large quantities of plasmid DNA at standard research and pre-clinical grades.

Profile Dr Yang

Dr.L.C.Yang is the Chief Executive Officer of Clone-E Therapeutics, Inc. which operates the Gene therapy laboratory, proteins or DNA microarray division and biotech related investments. Moreover, Clone E Therapeutics is a DNA based therapeutic company for ASP lightening cream or KGF solution in renew, revitalize, and repair for acne. Dr Yang, a leading Taiwan-based biotech entrepreneur, is the founder chairman of Clone-E Theraputics Inc, a private Research and Development organization. He holds several non executive director positions in biotech companies based in Europe, USA and India and is also the biotechnology advisor to several government agencies in Asia. Dr Yang has obtained his doctoral degree from Taiwan and was the recipient of postdoctoral research fellowship from University of California at Sandiego, Outstanding resident research award and National science council award. He has over 20 years of experience in the global healthcare and biotech industry. He was acting as chief of anesthesiology from 1999 to 2009. He was trying very hard to hold his daily administrative work and research works together day by day. He does appreciate that my team members provide the strong supports and encouragements when he has neither the resources or the energy to help himself. Importantly, he has published more than 20 gene therapy papers in international articles. Now, he is working as Associate Professor of Anesthesiology and Gene Therapy Laboratory, E-DA Hospital, I-SHOU University. He is highly ambitious and do right thing and think right is his strength. Dr. Yang has strong believes in non-viral gene delivery and set up animal models for pain, neurodegenerative disorder, skin disorders, bone disorders, and cancer. He transforms medical research into biotech oriented research. Besides, DNA vaccines for cancer, infectious disease, pain, and morphine addition, gene therapy, and stem cell research needs long term and continuous international cooperative strenuous efforts.

How to establish the international cooperation, it is time consuming and highly costs. Moreover, administrative departments of both sides should provide substantial supports and the executive team must be passionate, persevere, and patient to solve all the cooperative details, projects and tasks. In another word, it’s indeed difficult for any international cooperative projects, therefore, high quality and rapid decision making, integrating, and negotiating capabilities are very significant. Moreover, administrative efforts must have an authentic time because topics, budget, and researchers could be changed rapidly in competitive research fields. In order to establish the international cooperation, we must deliberate upon the sustainability and time-limit. Probably, these extremely small and annoying administrative works could impede outstanding investigators’ efforts that will result in disagreement and misunderstandings of both teams. Therefore, all the team personnel have to overcome the barriers. We believe that we need to continue to pursue novel technology and knowledge that promote strong career growth and quality improvement in research and products.
Together, we can make difference and get there.

Gene Therapy Publication
Tan PH, Yang LC, Shih HC, Lan KC, Cheng JT. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther. 2005 Jan;12(1):59-66.
Wu PC, Yang LC, Kuo HK, Huang CC, Tsai CL, Lin PR, Wu PC, Shin SJ, Tai MH.Inhibition of corneal angiogenesis by local application of vasostatin. Mol Vis. 2005 Jan 13;11:28-35
Chuang YC, Yang LC, Chiang PH, Kang HY, Ma WL, Wu PC, DeMiguel F, Chancellor MB, Yoshimura N Gene gun particle encoding preproenkephalin cDNA produces analgesia against capsaicin-induced bladder pain in rats. Urology. 2005 Apr;65(4):804-10.
Chuang IC, Jhao CM, Yang CH, Chang HC, Wang CW, Lu CY, Chang YJ, Lin SH, Huang PL, Yang LC. Intramuscular electroporation with the pro-opiomelanocortin gene in rat adjuvant arthritis. Arthritis Res Ther. 2004;6(1):R7-R14.
Yang CH, Shen SC, Lee JC, Wu PC, Hsueh SF, Lu CY, Meng CT, Hong HS, Yang LC. Seeing the gene therapy: application of gene gun technique to transfect and decolour pigmented rat skin with human agouti signalling protein cDNA. Gene Ther. 2004 Jul;11(13):1033-9.
Lee TH, Yang LC, Chou AK, Wu PC, Lin CR, Wang CH, Chen JT, Tang CS. In vivo electroporation of proopiomelanocortin induces analgesia in a formalin-injection pain model in rats. Pain. 2003 Jul;104(1-2):159-67. Chuang YC, Chou AK, Wu PC, Chiang PH, Yu TJ, Yang LC, Yoshimura N, Chancellor MB. Gene therapy for bladder pain with gene gun particle encoding pro-opiomelanocortin cDNA. J Urol. 2003 Nov;170(5):2044-8. Lin CR, Yang LC, Lee TH, Lee CT, Huang HT, Sun WZ, Cheng JT. Electroporation-mediated pain-killer gene therapy for mononeuropathic rats. Gene Ther. 2002 Sep;9(18):1247-53. Lu CY, Chou AK, Wu CL, Yang CH, Chen JT, Wu PC, Lin SH, Muhammad R, Yang LC. Gene-gun particle with pro-opiomelanocortin cDNA produces analgesia against formalin-induced pain in rats. Gene Ther. 2002 Aug;9(15):1008-14. Lin CR, Tai MH, Cheng JT, Chou AK, Wang JJ, Tan PH, Marsala M, Yang LC. Electroporation for direct spinal gene transfer in rats. Neurosci Lett. 2002 Jan 4;317(1):1-4.

Bookmark and Share

Close Bookmark and Share This Page

Save to Browser Favorites / Bookmarks

Ask backflip blinklist BlogBookmark Bloglines BlogMarks Blogsvine BuddyMarks BUMPzee! CiteULike co.mments Connotea del.icio.us

Digg diigo DotNetKicks DropJack dzone Facebook Fark Faves Feed Me Links Friendsite folkd.com Furl Google

Hugg Jamespot Jeqq Kaboodle kirtsy linkaGoGo LinkedIn LinksMarker Ma.gnolia Mister Wong Mixx MySpace MyWeb

Netvouz Newsvine oneview OnlyWire PlugIM Propeller Reddit Rojo Segnalo Shoutwire Simpy Slashdot Sphere

Sphinn Spurl Squidoo StumbleUpon Technorati ThisNext Twitter Webride Windows Live Worlds Movies Yahoo!

Email This to a Friend

Copy HTML: 

 If you like this then please subscribe to the RSS Feed.

Powered by Bookmarkify™

More »